Boehringer Aces Phase III Pulmonary Fibrosis Trial, Plans FDA Application

Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and inflammation in the lungs, met its primary endpoint in a late-stage study.